The Evaluation of the Use of a Paper Tracking Form to Improve Provider Adherence to Lipid Guidelines by Ladd, Diane
Graduate Theses, Dissertations, and Problem Reports 
2011 
The Evaluation of the Use of a Paper Tracking Form to Improve 
Provider Adherence to Lipid Guidelines 
Diane Ladd 
West Virginia University 
Follow this and additional works at: https://researchrepository.wvu.edu/etd 
Recommended Citation 
Ladd, Diane, "The Evaluation of the Use of a Paper Tracking Form to Improve Provider Adherence to Lipid 
Guidelines" (2011). Graduate Theses, Dissertations, and Problem Reports. 3073. 
https://researchrepository.wvu.edu/etd/3073 
This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research 
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is 
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain 
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license 
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, 
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. 
For more information, please contact researchrepository@mail.wvu.edu. 
 
 
The Evaluation of the Use of a Paper Tracking Form to 








Doctoral Research Project submitted to the  
School of Nursing 
at West Virginia University 
in partial fulfillment of the requirements  








Susan McCrone, PhD, Chair 
Lisa Hardman, PhD 

















The Evaluation of the Use of a Paper Tracking Form to 
Improve Provider Adherence to Lipid Guidelines 
 
 
Diane Ladd, MSN, FNP-BC 
 
 
Heart disease is the leading cause of death in men and women in the United States.  Significant 
research into the risk factors for cardiovascular disease has been done, and the effect of 
hyperlipidemia on cardiovascular risk has been well documented.  Recent research has shown 
that there is a lack of adherence to lipid guidelines by primary care providers.  Failure to follow 
clinical guidelines for lipid disorders leads to increased cardiovascular morbidity and mortality.  
The objective of the project was to evaluate whether a simple, paper-based, lipid tracking form 
could improve provider adherence to current lipid guidelines.  This descriptive study used a pre-
post test design.  Baseline adherence to lipid guidelines was determined by chart review of a 
random sample of current practice patients.  The lipid-tracking form was placed on the charts of 
all patients seen for routine office visits during a specified time frame.  After the lipid-tracking 
form collection period was completed, a random sample of those patients was reviewed to 
reassess adherence to lipid guidelines. The post-implementation date was compared to the 
baseline data.  The use of the lipid-tracking form did demonstrate an improvement in adherence 
to lipid guidelines as demonstrated by an increase in the number of patients who had a 
documented LDL goal (p=0.000).  In practices without electronic medical records, this simple, 
inexpensive, paper-based tool can help providers improve adherence to lipid guidelines. 
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Chapter I: Introduction 
Heart disease is the leading cause of death for men and women in the United States 
(Center for Disease Control and Prevention [CDC], 2009).   Coronary heart disease (CHD), the 
narrowing of the coronary arteries due to fatty build-up of plaque, caused 425,425 deaths in the 
U.S. in 2006 (American Heart association [AHA], 2006).  The American Heart Association and 
National Heart, Lung, and Blood Institute (NHLBI) estimated that the direct and indirect cost of 
cardiovascular disease in the U.S. for 2009 was 475.3 billion dollars (AHA, 2010).  Direct costs 
include healthcare providers and medications, and indirect costs refer to the loss of productivity 
from disability and death.  The economic cost can be measured, but the true human cost of 
debility, suffering, and death is incalculable. 
Background and Significance  
Statement of the problem. 
Failure to follow clinical guidelines for hyperlipidemia (HLD) screening, treatment, and 
follow-up leads to increased cardiovascular morbidity and mortality, which is a significant 
healthcare burden in money, time, and disability. 
Description of the problem.  
Heart disease is the leading cause of death in most ethnic groups in the United States 
including African Americans, American Indians or Alaska Natives, Hispanics, and Caucasians, 
while for Asians, heart disease is second to cancer (CDC, 2009).  The heart disease death rates 
per 100,000 persons in the United States are highest in Blacks (662) and second highest in 
Caucasians (529) (CDC, 2009).  The heart disease death rates in Michigan (per 100,000), where 
this project occurred, are highest in ethnic populations.  American Indians had the highest heart 
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disease death rate (805), and African Americans had the second highest heart disease death rate 
(709), while whites had a rate of 561.  Midland County Michigan‟s heart disease death rate was 
highest in American Indians (759), second highest in African Americans (659), and third highest 
in whites (580).  Overall Midland‟s heart disease death rate was higher than the United States for 
total population (585 v. 536), more than double for American Indian (759 v. 352), more or less 
equivalent for African Americans (659 v. 662), higher for Hispanics (409 v. 348) and higher for 
whites (580 v. 529) (Figure 1). Sager et al. (2010) calculated that adherence to lipid guidelines 
for cholesterol targets would prevent 50-80 heart attacks, strokes, and cardiovascular disease 
deaths per 1000 persons over a ten-year period.  
The INTERHEART study (Yusuf et al., 2004), a large multi-ethnic case-control study, 
that was conducted in 52 countries has shown that there are nine easily measured cardiovascular 
risk factors that account for over 90% of the risk of acute myocardial infarction and other 
cardiovascular problems (lipids, smoking, hypertension, diabetes, obesity, diet, physical activity, 
alcohol consumption, and psychosocial factors).  The most significant risk factor is 
hyperlipidemia (Yusuf et al., 2004).  Hyperlipidemia is the presence of elevated lipid and 
lipoprotein levels in the blood.  The link between lipid abnormalities especially increased low-
density lipoprotein (LDL) levels and cardiovascular risk has been well established (Karthikeyan 
et al., 2009).  LDL is the primary atherogenic lipid particle, and it is directly related to the 
development of atherosclerosis (Jones, 2010). 
Data from the American Heart Association (2010) shows that approximately 102.2 
million adults in the United States have total cholesterol levels over 200 mg/dl.  The prevalence 
of elevated total cholesterol (> 200 mg/dl) is highest in Hispanics at 51.1%.  It is second highest 
in whites 45.0%.  Of the ethnicities studied, the prevalence of elevated total cholesterol (>200 
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mg/dl) was lowest in Blacks at 40.2%.  From those about 35.7 million have total cholesterol 
levels greater than 240 mg/dl.  Utilizing the National Health and Nutrition Examinations Survey 
(NHANES) data, the AHA further subdivided the data by ethnicity (Black, Hispanic, and White), 
gender, and measures of increased cardiovascular (CV) risk (total cholesterol > 240 mg/dl, LDL 
> 130 mg/dl, and HDL < 40 mg/dl).  Additional data for total cholesterol >240 mg/dl showed the 
prevalence to be highest in Hispanics at 16.8%, followed by Whites at 15.3%, and then Blacks at 
10.9%.  The prevalence of LDL >130 was found to be highest in Hispanics at 42.7%, second 
highest in Blacks 34.4% and lowest in Whites 31.5%.  In addition, the AHA also provided 
prevalence data for HDL < 40.  The highest prevalence was highest in Hispanics at 29.3%, 
second in Whites at 25.4%, and lowest in Blacks at 14.7% (Figure 2). 
Coronary heart disease is usually caused by atherosclerosis (a buildup of fatty material 
and plaque inside the coronary arteries).  Atherosclerosis is progressive and begins early in life.  
Forensic data from the Pathologic Determinants of Atherosclerosis in Youth (PDAY) study has 
shown the presence of fatty streaks in segments of the arterial system of all teenagers autopsied 
(McGill & McMahan, 1998).  In addition, they found fatty plaques in the aorta and coronary 
arteries that increased with age.  Despite decades of research on lipids and coronary risk, there is 
still controversy over which lipid measurement is the most accurate predictor of cardiovascular 
risk.  Current guidelines from the National Cholesterol Education Program: Adult Treatment 
Panel-III (ATP-III) has identified low-density lipoprotein (LDL) as the primary target for lipid-
lowering therapy for the reduction cardiovascular risk (Pasternak, 2002).   
There is sufficient evidence from clinical trials that identifies an association between a 
decrease in cardiovascular morbidity and mortality with the decrease in atherogenic particles 
(Jones, 2010).  This has been demonstrated in patients with and without pre-existing 
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cardiovascular disease (Corrao, Conti, Merlino, Catapano, & Mancia, 2010).  Despite the 
abundance of evidence demonstrating the benefits of lipid control, there is still a significant 
failure of providers to appropriately screen, treat, or assign appropriate goals for lipid 
management (Sager et al., 2010).  Therefore, the purpose of this project is to evaluate the use of a 
paper-based lipid tracking tool on provider adherence to lipid lowering guidelines.   
Theoretical Framework 
One theory that can be used to guide the implementation of new guidelines, protocols, or 
practice changes is Rogers‟ Diffusion of Innovations Theory (Rogers, 1962).  This theory is used 
to describe how, why, and at what rate innovations are adopted and disseminated.  Contributions 
from other disciplines impacting this theory include: anthropology, sociology, education, and 
industrial and medical sociology (Ryan, 1943).  One of basic premises of this theory is that 
innovation is adopted slowly during the beginning of the process then, once it is perceived to be 
beneficial, it is adopted more quickly. There are distinct elements in the Diffusion of Innovations 
Theory. They include: types of communication, time, rate of adoption, and the type of system or 
group for which the innovation is intended.  For this capstone project, the site specific needs and 
deficiencies were taken into consideration.  Communication regarding the project was in written 
form, as well as verbal, to provide concrete information and references for the staff.  The type of 
system (small private practice) was taken into consideration in the project design.   
Rogers‟ Diffusion of Innovations Theory is a five-step process.  The five steps are: (1) 
knowledge; (2) persuasion; (3) decision; (4) implementation; and 5) confirmation (Figure 3).  
The knowledge step involves gaining and recalling knowledge about the innovation.  The 
persuasion step is when an individual becomes interested in the innovation, shares with others 
the positive role of the innovation within the group, and gathers support for the innovation within 
IMPROVING PROVIDER ADHERENCE TO LIPID GUIDELINES 5   
 
the system.  During the decision making step, additional information is gathered and the 
innovation is initially adopted or rejected.  The implementation step is when the innovation is 
utilized on a routine basis, and its usefulness and barriers can be determined.  The fifth step of 
confirmation is when the group recognizes the benefits and integrates the innovation into the 
systems ongoing routine (Sharma & Kanekar, 2008; Martin, 2009).  This investigator has 
identified other steps that may be necessary when implementing guidelines, protocols, or practice 
changes.  Rogers (1962) proposed that in the decision step the innovation will either be adopted 
or rejected.  This investigator proposed that rather than outright rejection, the next step, if the 
innovation is not adopted, would be initial rejection.  After initial rejection, there should be a 
reevaluation of the proposed innovation to assess its lack of adoptability.  If it is determined that 
the innovation is still appropriate to the system, and should be adopted, then it should be re-
introduced to the system beginning at the knowledge step. However, if it is determined that the 
innovation is not appropriate for the system, the last step would be final rejection.  Once an 
innovation has gotten to the final rejection step, it should not be reintroduced back into the same 
system without changes (Figure 4). 
Another significant factor in the use of this theory is identifying the rate of adoption. 
Each innovation is adopted at a different rate, and the speed at which the new innovation is 
adopted is determined, in part, by the adopter categories.  Rogers (1962) describes five adopter 
categories: innovators, early adopters, early majority, late majority, and laggards.  Innovators are 
usually the first to adopt an intervention.  They are usually risk takers and tend to be younger in 
age.  Early adopters are the second fastest category of adopters.  They tend to have a high degree 
of leadership.  The early majority are individuals who adopt after varying lengths of exposure to 
the innovation.  These adopters take longer than the first two groups and tend to be slower in 
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adopting.  The late majority adopts the innovation only after other members of the group have 
adopted it.  The late majority tend to be skeptical and wait to see what others have done.  The 
laggards are the last to adopt an innovation and are generally averse to change. The breakdown 
of these categories forms a normal distribution curve (Figure 5). 
In addition to the adopter categories, Rogers (1962) has described factors that influence 
the rate of adoption.  These include: relative advantage, compatibility, complexity, 
trialability/testability, and observability.  The relative advantage is the perceived advantage of 
the innovation within the group or system.  Compatibility refers to the amount of compatibility 
the proposed innovation has within the already existing system or structure as well as values and 
needs of the adopters.  Complexity involves not only the amount of work required to incorporate 
innovation within the group or system but also the perceived barriers to adopting the innovation. 
Trialability/testability refers to the amount to which an innovation can be tried on a limited basis.  
Observability is the amount to which the results of the innovation are visible to others.  It is 
easier for people to adopt and accept an innovation if they can easily see the results (Decivita & 
Dasgupta, 2007).  The lipid-tracking tool provides an at-a-glance record that shows the progress 
(or lack thereof) of the patient lipid control and increases the observability of the innovation 
(practice change).  In addition, the at-a-glance style of the form will reinforce the relative 
advantage (not having to look through the chart for history and lipid trends) of the innovation.  
The innovation is not complex, and there are no significant barriers such as need for specialized 
knowledge or technology. 
This theory was useful in implementing structured screening, treatment, and follow-up 
protocols and practice changes for the evaluation and treatment of hyperlipidemia.  The first 
stage is the stage of knowledge attainment.  During this stage, knowledge of the new guidelines 
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and the rationale for change was communicated to all members of the health care team.  It is 
important to stress that these guidelines were developed after many years of research and review.  
Opportunities for team members to ask questions and express concerns were provided.  Once the 
information and rationale on the new guidelines had been given to the team members, it was 
important to identify those who were actively seeking more information regarding the 
implementation and guidelines.  The innovators and early adopters were utilized to help 
incorporate the innovation into clinical practice.  
The second stage was the persuasion stage.  Employees who showed interest in the 
guidelines and interventions and were proactive in seeking information and providing solutions 
were utilized to assist in bringing others on board and spearheading group-wide changes.  In 
addition, during this stage, barriers and problems related to the innovation were identified and 
addressed.  It was beneficial to use the innovators and early adopters to help develop specific 
processes for implementation of the guidelines. 
In the third stage, the decision-making process, the initial decision to incorporate any 
changes was made.  During this process, it was easy to identify those who have not yet adopted 
the new guidelines or who were resistant to change.  If there were a significant number of non-
adopters in the group, it might have been prudent to delay the implementation of the guidelines 
and redirect efforts into the knowledge and persuasion stages.  When the decision to implement 
the new guidelines was made, then formal planning began.  In order to plan a significant practice 
change, all team members needed to fully understand the processes involved.  This included 
development of new tools and restructuring of processes.  During this stage, additional barriers 
and problems were identified and solutions sought.  The intermediate stage of initial rejection led 
to a reevaluation of the innovation (practice change) and the system.  If the innovation fails to be 
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adopted, then it would be at the initial rejection phase, and the reevaluation will would allow the 
innovation to be assessed and reintroduced at the beginning, knowledge step, to improve the 
chance that it would be adopted.  The innovators and the early adopters can be utilized for the 
reevaluation and re-introduction. 
Stage four is the implementation phase.  During this stage, members of the group worked 
together to implement the guidelines and processes.  The goal was that a majority of the team 
members would adopt the new guidelines.  It has been predicted that if 50% of the group support 
an innovation, it has a greater than 80% chance of successful implementation (Agyeman et al., 
2009).  Stage five, the confirmation stage, was when the change or guidelines and processes 
would be formally adopted.  At this time, the new guidelines and protocols would be put into 
routine clinical use.  It is important to recognize that even though the intervention or change 
might now be part of routine practice, it still needs to be evaluated for effectiveness.  
While the Diffusion of Innovations theory is a good model for introducing clinical 
guidelines or practice changes, it does not come without problems.  The implementation of a new 
guideline, process, or practice change is not a fast process, and that needs to be effectively 
communicated.  The initial adoption is a slow process that speeds up as more members of the 
system agree with the innovation or change.  Expectations of a quick adoption process and 
implementation can lead to problems, disillusion, and ultimately failure to implement the 
innovation.  Interventions that are preventative in nature are harder to adopt because there is no 
immediate measurable benefit.   
The usefulness of this theory has been demonstrated in the corporate, athletic, and 
practice settings.  One of the best resources for the use of this theory is to identify and involve 
innovators who are excited about practice change, have appropriate levels of knowledge, and are 
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considered leaders within the group.  One of the barriers to the use of this theory in the clinical 
practice setting may be a culture of resistance to change. Another barrier could be the general 
lack of knowledge and understanding regarding the generation of new guidelines and their role in 
prevention.  One of the best ways to assist in implementing any practice change especially in the 
clinical practice setting is to recognize that change occurs slowly and to begin efforts early in 
anticipation of a needed practice change. 
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Chapter II: Review of the Literature 
Search Strategy 
 The articles for review were identified by searching electronic databases. The databases 
searched were: the Cochrane Library, Academic Search Complete, CINAHL, and Medline.  The 
keywords used were: adherence, guidelines, and lipids.  No systematic reviews were identified 
from the search.  The initial search yielded 319 results.  The results were narrowed to include 
only articles published within the last five years, human studies, articles published in peer-
reviewed journals, and available in English.  Seven studies were selected for the review based on 
the strength of evidence and relevance to the problem.  The seven studies included: one 
randomized controlled trial (Hung, Lin, Hwang, Tsai, & Li, 2010), and six cross-sectional 
surveys (Barham et al., 2009; Gowani et al., 2009; Laforest et al., 2008;  Lewis, Robinson, Fox, 
& Grandy, 2010; Sager et al., 2010; Vulic, Lee, Dede, Lopez, & Wong, 2010). 
Literature Review 
 The randomized controlled trial (RCT) evaluated the use of a paper chart reminder on 
guideline adherence in lipid management in Taiwan (Hung et al., 2010).  The study randomized 
patients with angiographically proven CHD who were not on lipid-lowering therapy (LLT) into 
either the control group or the intervention group.  The intervention was a paper reminder that 
was placed on the chart that stated “Statins can be beneficial to patients with documented 
coronary artery disease regardless of their LDL level.”  Below that statement was the detailed 
reimbursement policy for the National Health Insurance of Taiwan.  If no action was taken after 
three months, a second reminder was placed on the charts.  The study had two end points; the 
primary endpoint was a new prescription for LLT (statin or ezetimibe) during the six month 
follow-up period, the secondary endpoint was the composite of LLT or repeat lipid profile within 
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six months.  The investigators randomized 194 patients, 92 to the study group and 102 to the 
control group.  The groups were well-matched.  The inclusion and exclusion criteria were well 
described.  There were new LLT prescriptions in 14.1% of the study group and 8.8% of the 
control group.  The odds-ratio (OR) for LLT was 1.70 (P=0.248, 95% CI: 0.69-4.19).  The 
secondary endpoint showed better results in the study group.  The study group had repeat lipid 
panels in 59.8% of the patients.  The control group only had 35.3% of patients with repeat lipid 
panels.  The OR for the secondary endpoint was 2.81 (P=0.001, 95% CI: 1.57-5.04). The 
investigators were unable to see a significant improvement in the primary endpoint, but did see 
an improvement in the secondary endpoint.  The inclusion of the reimbursement policy on the 
reminder is thought to be a significant factor in the lack of improvement in the primary endpoint.  
The reimbursement policy (which does not reimburse unless LDL ≥ 130) contradicts the other 
statement that the use of a statin is beneficial regardless of LDL level.  The studies strength is its 
RCT design.  Its weaknesses are: the small sample size, lack of ethnic diversity, and policy 
restrictions that affected the primary endpoint. 
 There were six cross-sectional surveys (CSS) reviewed.  The first CSS evaluated the 
appropriateness of cholesterol management in primary care.  The investigators (Barham et al., 
2009) evaluated the appropriateness of cholesterol management in relation to cardiovascular risk 
and sex.  They examined medical records from 60 community practices in North Carolina that 
were participating in a randomized practice-based trail (Guideline Adherence for Heart Health).  
They investigated 5031 patients aged 21-84 years.  The investigators used a multivariate logistic 
regression to assess whether age, sex, race, diabetes, cardiovascular disease, ATP-III risk 
category, or pre-treatment LDL influenced treatment for lipid disorders.  They found that 
screening rates were higher in those who were older and those who had diabetes or 
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cardiovascular disease.  However, they did not see any large difference in screening rates by sex.  
They found that older age was associated with less appropriate lipid treatment (OR 0.91, P=0.01) 
even though older adults had higher screening rates.  In addition, they found that patients with 
LDL ≤ 130 and those in the low cardiovascular risk category were more likely to be managed 
appropriately when compared with those whose LDL ≥ 190 and those at high risk (OR 18.8, P < 
0.001; OR 27.5, P <0.001).  Investigators also found that of the 375 patients eligible for 
treatment, those with LDL levels ≥ 131 and ≤ 159 were less likely to be treated compared to 
those with LDL ≥ 190 (OR 0.15, P=<0.001).  They concluded that adherence to ATP-III 
guidelines is more challenging in intermediate-risk and high-risk patients than for those at low-
risk, and patients in those categories were significantly less likely to be managed appropriately.  
This study‟s strength is its large sample size and use of multiple practices.  It weaknesses are in 
the CSS design and the data (medical record) abstraction, which may not have captured all of the 
actual patient data. 
 Another cross-sectional survey evaluated LDL goal attainment in patients receiving LLT 
(LaForest et al., 2008).  The investigators analyzed 2727 patients obtained from a French 
computerized general practice database.  The patients were selected from randomly chosen 
providers in the database.  They included patients who had a diagnosis of dyslipidemia 
(hyperlipidemia) and had a visit within the selected time frame.  In addition, the patient had to be 
treated with at least one lipid-lowering agent (LLA). The investigators examined the number of 
patients who reached therapeutic objective (TO).  They found that only 58.5% of the high-risk 
patients met the TO for the overall analysis. When the data was analyzed based specifically on 
cardiovascular risk, the investigators found that significant differences were observed especially 
at the high risk level. They found that only 42% of high risk patients met the TO (P < 0.0001).  
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In addition, they also found that when patients had a history of CVD and diabetes, there was a 
higher percentage (57%) of patients that had reached TO compared to patients with only CVD 
(42%), and those who were without CVD but at high risk (32%) and being treated as primary 
prevention (P< 0.0001).  The strengths of this study are its large sample size and the use of 
random selection of practices from which to collect data, as well as the large number of practices 
sampled.  Its weaknesses are using guidelines other than ATP-III, although they are similar, and 
the use of multiple risk categories and sub-categories. 
 The third cross-sectional survey examined the underutilization of cardiovascular 
medications in at risk individuals (Lewis, Robinson, Fox, & Grandy, 2010).  The investigators 
identified patients from the SHEILD (Study to Help Improve Early evaluation and management 
of risk factors Leading to Diabetes) study who were at risk for or with a history of CVD events 
such as MI, stroke, or revascularization.  CHD risk was defined using the ATP-III guidelines.  
The respondents were divided into three categories: high CHD risk (7510), moderate CHD risk 
(4823), and low CHD risk (5307).  The investigators found that the use of LLT was very low in 
each group (21.5%, 13.0%, 5.5% respectively; p < 0.001).  After adjusting for age, gender, and 
geography, they found that high and moderate CHD risk groups were more likely to have gotten 
LLT than the low-risk participants (p < 0.001).  The high-risk group was over four times more 
likely to have had statin therapy (OR 4.60, 95% CI: 3.54-5.97) and the moderate-risk group was 
over three times more likely (OR 3.13, 95% CI: 2.45-3.99) to have statin therapy than the low-
risk group.  In addition, they found that within the high-risk group, participants with a history of 
prior CVD event got LLT more often (25%) than those with type II diabetes (19.5%; p=0.02).  
The investigators also found that participants who had type II diabetes were receiving LLT more 
often than those in the moderate and low risk groups (p < 0.001).  This study‟s strength is its 
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large sample size and use of established guidelines for quantifying risk (ATP-III). Its weaknesses 
are its use of self-report data and its examination of only the use of LLT and not the management 
of HLD. 
 Another cross-sectional survey assessed adherence to published lipid treatment guidelines 
among cardiologists in Pakistan (Gowani et al., 2009).  The investigators developed a structured 
questionnaire to collect information regarding: fundamental knowledge of the basic practices in 
lipid management, evidence of sex or age bias, and demographics including continuing medical 
education (CME) activities.  The questionnaire was piloted with ten cardiologists who were not 
part of the study.   Feedback from the pilot study provided information to the investigators, the 
questionnaire was shortened, and some of the language was changed to clarify some of the 
questions.  The study participants were 239 cardiologists from multiple centers in Pakistan who 
completed a questionnaire.  The questionnaire had a maximum score of 14.  In addition, data on 
the cardiologists‟ education, type of cardiology practiced, and exposure to continuing medical 
education (CME) was collected.  The median score on the questionnaire was nine.  The 
investigators found that there were fewer correct answers from the cardiologists in areas dealing 
with fundamental issues such as: initial choice of therapy (77.0 %); the maintenance of 
therapeutic dose after goal is attained (46.9%); and lack of aggressive treatment of LDL (16.7%).  
In addition, they demonstrated that the cardiologists indicated that there was bias regarding 
patient age in respect to different LDL goals (41.8%) and different thresholds for starting therapy 
(35.1%).  They also identified physician bias towards patients of different sexes.  They noted that 
there were reported differences in thresholds for starting therapy in women (43.5%) and different 
LDL targets in women (46.4%).  They found that 73% of the cardiologists who reported a bias 
were less aggressive in treating women.  In the adjusted analysis, it was noted that years of 
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experience, practice in interventional cardiology, and exposure to CME was associated with 
increased knowledge (P=0.005; P=0.041; P=0.001, respectively).  The study‟s strengths are the 
use of a pilot study prior to implementation as well as the use of well recognized lipid guidelines 
(ATP-III).  The weaknesses are: absence of reliability and validity information on the 
questionnaire, lack of ethnic diversity, and a lack of regulation of medical specialty practice in 
Pakistan however, that was addressed somewhat by the study design. 
 The fifth cross-sectional survey evaluated the extent of adherence to recommended 
cardiovascular therapies (Vulic et al., 2010).  The investigators used a multi-ethnic sample with 
CHD.  They assessed adherence to recommended therapies for CHD in representative sample of 
364 adults with CHD selected from the National Health and Nutrition Examination Survey 
(NHANES) database.  They calculated the proportion of patients who were receiving 
recommended therapy.  The investigators found the treatment rates for LLT were lower in 
Hispanics (27%) and non Hispanic Blacks (42%) than in non-Hispanic Whites (p < 0.01).  In 
addition, they also found that lipid-lowering treatment rates were lower in females (50%) as 
compared to males (67%)  (p < 0.01).  The study‟s strengths are its use of the NHANES database 
and use of a multi-ethnic sample.  Its weaknesses are the small sample size and lack of laboratory 
data. 
 The final cross-sectional study reviewed physicians‟ perception of LDL goals based on 
guideline recommendations (Sager et al., 2010).  The investigators asked 907 physicians to 
determine the LDL goal for 30 of their patients with HLD based on current guidelines (ATP-III).  
They divided the 25,250 patients into three different LDL target groups (< 100, < 130, and < 
160).  The investigators used a logistic regression to evaluate whether the physicians‟ 
incorporated risk factors and comorbidities correctly to determine the proper LDL target.   They 
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found that the physicians identified the correct LDL target in only 55.1% of male patients versus 
49.1% of females (P < 0.001).  The data showed that in the group with LDL target < 100, the 
correct assignment was most often assigned to male patients with a history of CAD and 
myocardial infarction (77.1%).  The investigators found the correct LDL goal of < 100 in 
patients with CAD and concomitant disease.  The found the rates to be: CAD and CABG 
(76.6%), CAD and diabetes (69.6%), CAD without CABG (61.3%), CAD without diabetes (61.2 
%), and CAD without MI (58.4%).  They also found in all patients with CAD, that the correct 
LDL goal was assigned more often in men than in women (67.6% v. 59.7%; p<0.001).  The data 
was placed in quartiles based on guideline knowledge.  They found that the patients of the 
physicians in the top quartile (>90% correct LDL goals) had lower LDL levels than those in the 
other quartiles (p < 0.001).  The strength of this study is its large sample size.  Its only significant 
weakness is the cross-sectional survey design. 
Synthesis 
 The RCT (Hung et al., 2010) showed that the use of a paper-based clinical reminder 
could modify provider behavior in assessing lipid values.  Unfortunately, this study did not show 
an increase in the use of LLT.  The inclusion of the reimbursement policy for LLT on the 
reminder form significantly affected the use of LLT in the participants, which was the primary 
outcome.  The reimbursement policy contradicted the other statement that “statins can be 
beneficial regardless of LDL level”.  It is probable that the absence of the reimbursement policy 
statement would have led to a better outcome in terms of better use of LLT.  While the study did 
not meet its primary outcome, it did adequately demonstrate that the use of a paper-based clinical 
reminder could modify provider behavior. 
IMPROVING PROVIDER ADHERENCE TO LIPID GUIDELINES 17   
 
 The six cross sectional surveys clearly demonstrated that there is a lack of provider 
adherence to lipid guidelines.  The studies addressed different aspects of adherence to lipid-
lowering guidelines.  Two of the studies (Barham et al., 2009; Laforest et al., 2008) examined 
lipid management and found that those at high risk were less likely to receive appropriate 
treatments or reach therapeutic objective (goal).  Two of the studies reviewed treatment rates (for 
LLT) and utilization of LLT (Lewis et al., 2010; Vulic et al., 2010).  Those studies showed that 
the treatment rates were low for all groups studied.  Two of the studies (Gowami, et al., 2009; 
Sager et al., 2010) evaluated provider knowledge and adherence to lipid-lowering guidelines and 
demonstrated that there was a distinct lack of provider knowledge as well as a failure to identify 
correct LDL targets.  In addition, three of the studies (Gowani et al., 2009; Sager et al., 2010; 
Vulic et al., 2010) showed that providers were more likely to treat and manage lipids more 
aggressively in men than in women.  Two studies (Barham et al., 2009; Vulic et al., 2010) 
demonstrated that there was age bias as older age was associated with less appropriate treatment.  
Also, one study found that there was a lack of adequate treatment in some ethnicities especially 
Hispanics and non-Hispanic Blacks (Vulic et al., 2010).  Four of the studies had large sample 
sizes (Barham et al., 2009; Laforest et al., 2008; Lewis, et al., 2010; Sager et al., 2010).  All four 
of these studies clearly showed that there is a lack of provider adherence to lipid guidelines.  This 
is especially noted in those patients in the high risk categories in all three of these studies 
(Barham et al., 2009; Laforest et al., 2008; Lewis, et al., 2010).  Other cross-sectional studies 
(Gowani et al., 2009; Vulic et al., 2010) with smaller sample sizes also showed that there was a 
lack of provider adherence to lipid-lowering guidelines.     
Overall the body of evidence from the cross-sectional surveys clearly demonstrates that 
not only is there a lack of provider adherence to lipid guidelines, but that those at high risk, some 
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minorities, and women are especially vulnerable to undertreatment.  There were no significant 
knowledge gaps identified. The RCT adequately showed that the use of a paper-based clinical 
reminder modified provider behavior.  The hypothesis for the project is that: the use of a simple 
paper lipid-tracking tool in a primary care practice (without EMR) will improve provider 
adherence to lipid-lowering guidelines and improve patient care.  The objective of the RCT is 
well matched to the hypothesis of the capstone proposal, that a paper based intervention can 
modify provider behavior.  The body of evidence substantiates the need for protocol change that 
includes a paper based clinical reminder to help modify provider behavior and improve provider 
adherence to clinical guidelines (ATP-III) for lipid disorders. 
Congruence of Organizations Strategic Plan to the Capstone Project 
 The goal of the practice is to provide high quality, efficient, ongoing comprehensive 
medical care for the patients it serves.  A large number of the patients have chronic medical 
conditions such as diabetes, hypertension, chronic kidney disease, and hyperlipidemia.  The 
primary goal of the project is to improve provider adherence to clinical guidelines for lipid 
disorders.  This is in line with the overall goals of the practice.  
Project Objectives 
The hypothesis for the project is that the use of a simple paper lipid-tracking tool in a 
primary care practice (without EMR) will improve provider adherence to lipid-lowering 
guidelines and improve patient care.  The specific objectives for the project after the protocol 
change are: (1) to educate the staff regarding lipid guidelines through the use of the lipid-
tracking form (LTF) and lipid guidelines; (2) to assess the baseline adherence to lipid guideline 
from chart review using the data collection form (DCF) and data prior to the intervention; (3) to 
demonstrate an increase in screening for lipid disorders after the intervention; (4) to identify 
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from the chart review after the protocol change an improvement in the number of patients with 
abnormal lipid values who are correctly diagnosed with hyperlipidemia (HLD); (5) to increase in 
the number of patients that have an identified LDL goal after the protocol change; (6) to increase 
the number of patients who have the correct LDL goal identified; (7) to identify an improvement 
in the number of patients who are given the correct medications for HLD; (8) to increase in the 
number of patients who are getting correct follow-up for lipid disorders.  It is anticipated that 
these changes will be both statistically and clinically significant.  
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Chapter III: Methodology 
Project Design 
This capstone project used a descriptive, retrospective, before and after design.  The 
project was designed to evaluate the use of a simple paper tracking form on provider adherence 
to lipid guidelines (ATP-III).  There was a pre and post intervention analysis and specific 
objective measurements of lipid guideline adherence were compared.  There was an analysis of a 
random sample of patients to determine baseline adherence to lipid guidelines prior to the 
intervention.  These patients were randomly selected from the practice database.   During a 
specific time frame, twenty-three consecutive days, the tracking form was placed on the charts of 
all patients coming to the office for routine office visits.  Patients coming to the office for joint 
injections or dermatological procedures were excluded.  The practice is relatively small, 
approximately 1500 active patients, with only three providers including the project leader.  All 
patients seen during the evaluation period received the intervention (lipid-tracking form) 
including those seen by the project leader, but that data was removed prior to analysis in order to 
eliminate bias.  After the intervention period, the lipid tracking forms were collected and 
analyzed.  A random sample of the lipid tracking forms were analyzed for comparison to the 
baseline data. 
Resources 
 This project did not require many resources other than the project leader‟s time.  Office 
supplies such as paper, ink, and photocopying were provided by the site.  Educational materials 
were already present at the site and provided by an outside vendor (non-pharmaceutical).  The 
data collection form and lipid tracking tool were developed and printed by the project leader.  
There is little or no need for additional involvement of ancillary staff as any work involved in the 
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project (making labs slips, scheduling appointments) was already part of their current work 
duties, and were not in excess.  The other providers in the practice were asked to complete the 
form at the time of the patient visit.  This did not significantly impact the time needed for each 
patient visit.  It took less than two minutes to complete the lipid tracking form.  Each provider 
did have a face-to-face in-service on the use of the form as well as written instructions 
(Appendix A).   
 The data collection form (DCF) was intended to collect specific objective data on 
measures of guideline adherence.  This form was used to collect the pre and post intervention 
data.  In addition, the form was used to collect baseline demographic data.  The data collected 
included: project identifier (no names were used), date of birth, age, date of last clinic visit, 
comorbidities (diabetes, coronary artery disease, peripheral vascular disease, stroke), family 
history of heart disease, date of last lipid profile, diagnosis of HLD, medications for HDL, date 
of follow-up lipid panel, LDL target, correct LDL target, and whether the patient was at or below 
LDL target (Appendix B).  These data tracking forms were completed by the project leader and 
were not intended for use by the other providers. 
 The lipid-tracking form (LTF) was intended it improve provider adherence to lipid 
guidelines by providing the needed information in one easily accessible place.  The form 
consisted of a grid that provided information on the patients‟ lipid values, medications, 
medication changes, planned follow-up, and comments (e.g. missed doses, side effects).  The top 
part of the form included areas for information about the patients‟ comorbidities (CVD risk), and 
their LDL goal (Appendix C).  In addition, a portion of the ATP-III guidelines (Appendix D) 
were printed on the form.  Also included on the form is the recommended follow-up.  This form 
was intended to be completed by the provider at the time of the patient visit. 
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Evidence of Key Site Support 
 The site for the implementation of the capstone project was a small independent Internal 
Medicine practice in Midland County, Michigan.  The practice owner was supportive of the 
project leader‟s participation in the DNP program.  There were multiple discussions between the 
practice owner and the project leader regarding the project and how it would fit in with the 
practice.  A signed letter allowing the project to be performed at the site was obtained (Appendix 
E). 
Procedure 
 The implementation of the practice change occurred in several steps.  Prior to 
implementing the practice change, multiple discussions were held with the other providers in the 
practice to review the lipid tracking form (LFT) and obtain input on the format.  The feedback 
was utilized in the development of the final form (Appendix C).  The providers were given a 
copy of the ATP-III quick reference guide and the Framingham risk charts (Appendices D & F).  
In addition, copies of these were placed in all of the exam rooms.  Instructions for the use of the 
lipid tracking form were given to each provider (Appendix A).  Verbal instructions were also 
provided.  The project was submitted the West Virginia University Institutional Review Board 
(IRB) for review.  It was reviewed by the IRB and determined to be exempt. 
 The evaluation period consisted of 23 consecutive business days.  The lipid tracking 
forms were placed on the charts of the eligible patients by the project leader.  This was done just 
before the patient visit, either the evening before or morning of the visit.  The project leader 
filled out preliminary information on the lipid tracking forms.  This included: age, gender, and 
the most recent lipid values.  The providers were expected to fill out the data on comorbidities, 
determine and document the LDL goal, and indicate medications and follow-up.  During the 
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evaluation period there were 336 forms placed on the charts.  Of the eligible charts, the forms 
were placed on 100% of the charts.  The forms were left on the charts during the entire 
evaluation period.  After the evaluation period the forms were retrieved.  Of the 336 forms that 
were deployed, 333 were retrieved (99.1%).  Since the forms were placed on the charts just prior 
to the patient visits, some forms were not eligible to be completed because the patient did not 
make their appointment.  Of the 333 forms that were collected 20 of those where on charts where 
the patient did not make their visit leaving 313 forms.  The sample was then further reduced by 
excluding the patients that were seen by the project leader yielding a 233 post practice change 
sample.  From this sample 100 forms were randomly selected for analysis.  Excluding the project 
leader only one of the two providers who participated in the evaluation of the practice change 
completed any of the forms.  That provider completed approximately 45% of the eligible forms.   
Evaluation  
 The evaluation of the project had several components.  The first component was the 
evaluation of baseline adherence to lipid guidelines.  This involved the collection of data on 100 
randomly selected patient charts on the data collection form (Appendix B) to track objective 
markers of adherence (screening, diagnosis, treatment, follow-up, identified LDL goal, and 
treatment to goal).  The second component examined two factors in the implementation of the 
practice change.  The percentage of patients who received the lipid-tracking form was 
determined.  This was accomplished by calculating the number of patients seen during the 
specified time frame and dividing that into the total number of patients who actually received the 
lipid-tracking form during that time.  This was calculated to be >99%.  In addition, provider 
compliance with the project was also calculated.  This was done by determining the number of 
patients who received the lipid tracking form and dividing that into the number of completed 
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lipid tracking forms.  This was also broken down by provider.  This was expected to be > 75%.  
This was to measure implementation of the practice change not patient adherence.  The third 
component was the determination of post-intervention adherence to lipid guidelines.  A random 
sample of the patient‟s lipid tracking forms were reviewed using the data collection tool and 
compared to the random patient sample that was analyzed prior to the intervention to determine 
if the lipid tracking tool improved provider adherence to lipid guidelines.  This evaluated specific 
areas of adherence.  In order to compare the results of two groups a chi-square test and 
independent t-test were used.  A p value of < 0.05 was set for statistical significance. 
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Chapter IV: Results 
Sample Characteristics 
 There are two samples that will be described in the remainder of this paper: (1) the 
baseline sample and; (2) the post practice-change sample.  The baseline sample (BLS) was a 
sample consisting of 100 randomly selected charts from the practice cohort.  This sample 
consisted of patients over the age of 20 who did not have the project leader as a primary care 
provider.  The post practice-change sample (PPS) consists of a random selection of 100 patients 
who received the practice change (LTF).  It consisted of patients who were seen by the other 
providers in the practice.  The patients who were seen by the project leader were excluded from 
selection.  The baseline sample (n=100) had a mean age of 67.73 years with a standard deviation 
of 14.098 years.  The minimum age was 37 years and the maximum age was 94 years.  The post-
practice change sample (n=100) had a mean age of 69.66 years with a standard deviation of 
12.173 years.  The minimum age was 41 years and the maximum age was 93 years.  An 
independent t-test confirmed that there was no statistically significant difference in the ages of 
the two samples (p=0.301).  The gender distributions in both the pre and post samples were also 
compared.  The baseline sample was 47% male and 53% female.  In the post practice-change 
sample was 51% male and 49% female.  A chi-square test showed there was not a statistically 
significant difference in gender in the samples (p=0.572).  Race/ethnicity was not analyzed 
because the baseline characteristic of the practice cohort is predominantly Caucasian (98.66%).  
This is consistent with the racial breakdown in Midland County (96.25%). 
Assessment of Baseline Adherence 
To determine baseline adherence to lipid guidelines the baseline sample of patients from 
the practice cohort were reviewed.  Specific criteria were tracked using the data collection form 
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(DCF).  The criteria were chosen to address the project objectives.  The objectives that were 
addressed in the analysis of baseline adherence included: (1) evaluation of patients who had 
proper screening; (2) determination of patients who had the correct diagnosis of hyperlipidemia; 
(3) the number of patients who had a documented LDL goal; (4) the number of patients who had 
the correct LDL goal; (5) evaluation of the use of correct medication to treat hyperlipidemia; and 
(6) evaluation of the number of patients who had appropriate follow-up.  The assessment was 
done on data that preceded the practice change.  The data collected included: date of visit, date of 
the most recent labs that preceded the visit, specific comorbidities (diabetes, coronary artery 
disease, and evidence of need for secondary prevention), lipid values, evidence of LLT, and 
follow-up.   
Screening. 
To determine adherence to screening recommendations, the time between the lab date 
and the visit date were calculated (lab-days).  In addition, follow-up lipid testing was also 
considered.  Based on the calculation of lab-days, it was determined that adequate adherence to 
lipid screening was achieved at baseline.  The mean number of lab-days (number of days 
between labs and visit) prior to the practice change was 129.77 days, the minimum number of 
days was 0 and the maximum was 1555.  Recommended screening for patients with chronic 
disease is annually (364 days) and the recommended screening for those without chronic disease 
is at least every 5 years (1820 days).  An independent t-test showed that there was no association 
between lab-days and patients who were not at or below goal (p=0.533). 
Assessment of diagnosis of hyperlipidemia. 
 The baseline sample was reviewed for patients with abnormal lipid values who did not 
have evidence of either a diagnosis of hyperlipidemia, (hyperlipidemia, dyslipidemia, or 
IMPROVING PROVIDER ADHERENCE TO LIPID GUIDELINES 27   
 
hypercholesteremia) or evidence of treatment with lipid lowering therapy.  There were not a 
significant number of patients who had abnormal lipid values who did not have a documented 
diagnosis or evidence of treatment with lipid lowering therapy. However the absence of 
documented LDL goals makes this difficult to ascertain.  The diagnosis of HLD is relative to the 
goal.  The project leader established estimated goals based on the evidence available for review.  
Based on the estimated goals there were six patients identified that did not have a diagnosis of 
HLD (either documented or evidence of LLT) and who were not at or below the goal.  A chi-
square test showed that this was not statistically significant (p=0.790).  At the competition of the 
project these patient charts were referred to the provider for further review. 
Documentation of LDL goal. 
 In the baseline sample there we no documented LDL goals in the charts reviewed.  
Because there were no documented LDL goals, there was not an opportunity to evaluate whether 
or not they were the appropriate goals.  However, the project leader estimated the LDL goals, 
based on the information that was available for review in the chart, to determine whether or not 
the patients were at or below goal.  Based on estimated goals determined by the project leader, it 
was found the 28% of the sample was not at or below goal, and that 72% of the patients were at 
or below the estimated goal.   
Assessment of medication usage to treat hyperlipidemia. 
 The baseline sample was also analyzed to review the use of medications in the treatment 
of hyperlipidemia.  In addition to the chart review, the electronic prescription system was also 
reviewed.  It was difficult to assess due to individual provider preferences for the use of different 
medications in the treatment of lipid disorders.  In addition, there was lack of adequate 
documentation regarding the medication choices, especially in those patients not treated with 
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statin therapy.  While there are appropriate rationales for the use of non-statin therapy, it is useful 
to have documentation on the reasoning behind the choice of non-statin therapy.  The data 
collection for this project grouped lipid-lowering therapy into four basic categories: 1) statin 
therapy, 2) Zetia only, 3) over-the-counter (including fish oil, red yeast rice, etc.), and 4) other 
(Welchol, Lovaza, etc.).  In the baseline, sample fifty-seven patients had documented therapy 
with statins, four were on Zetia alone, five were on over the counter therapies, and five were on 
other medications.  Comparison with the „at or below goal‟ (estimated) measure using a chi-
square test showed that there were at total of eight patients who were not receiving any treatment 
who were not at or below goal.  This was not statistically significant (p=0.814). 
Follow-up. 
Another indicator of adherence to lipid guidelines that was evaluated is the appropriate 
follow-up for patients with lipid disorders.  This includes visits and labs.  The baseline sample 
was used to determine baseline adherence to follow-up.  The determination of follow-up was 
calculated using chart review and the follow-up guidelines for patients with hyperlipidemia.  
These follow-up guidelines were also printed on the lipid tracking form.  The follow-up 
guidelines were developed in collaboration with the practice owner.  The recommended follow-
up was: (1) new diagnosis, change in medication or unstable, six to twelve weeks; (2) if stable 
and at goal, three to six months; and (3) patients with chronic disease, annual screening. The 
project leader reviewed each chart of the patients in the baseline sample.  The measure „follow-
up‟ used a discrete variable of yes/no.  Yes to indicate that there was appropriate follow-up 
ordered, and no to indicate absence of documented appropriate follow-up.  This looked 
specifically at provider actions (whether or not follow-up was ordered) not at patient compliance 
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with the orders.  In the baseline sample there were 22 patients who did not have appropriate 
follow-up and 78 who did.   
Evaluation of Post Practice-Change Adherence   
 The post practice change adherence to lipid guidelines was evaluated by comparing 
specific criteria from the baseline sample and the post practice change sample.  The specific 
criteria compared included: 1) documentation of an LDL goal, and 2) appropriate follow-up for 
lipids.  Age and gender were also compared in the two samples to determine if the samples were 
equitable.  The samples were determined to have similar distributions of age and gender; the 
details are described further in the sample characteristics section.   
Documentation of an LDL goal. 
 One of the project objectives was to increase the number of patients who had a 
documented LDL goal.  While the response was not as great as the investigator had originally 
anticipated, there was an increase in the number of patients who had documented LDL goals, 
which was statistically significant.  Overall there was a 26% increase in the documentation of an 
LDL goal.  A chi-square test showed that this was statistically significant (p=0.000).  Because 
only one provider completed the forms, that provider was solely responsible for the 26% 
increase.  The appropriateness of these documented goals was reviewed based on the information 
that was readily available in the chart.  It was observed that some of the LDL goals were more 
aggressive than those recommended based on the ATP-III guidelines.  This was specifically 
noted in patients with diabetes.  This was not considered an incorrect goal, because other 
guidelines recommend aggressive lipid lowering in patient with diabetes.  Analysis using the 
more aggressive LDL goals did not indicate and significant difference in the number of patients 
who were at or below goal. 
IMPROVING PROVIDER ADHERENCE TO LIPID GUIDELINES 30   
 
Follow-up. 
 The post practice change sample was compared to the baseline sample to determine if 
there was an increase in the number of patients who were given appropriate follow-up for lipid 
disorders.  There was an increase in the number of patients with the proper follow-up ordered 
after the practice change (82 v. 77) but it was not statistically significant (p=0.457).  There was a 
corresponding decrease in the number of patients who did not have follow-up ordered.  Twenty-
two patients in the baseline sample and eighteen in the post practice change sample. 
Other Analyses 
 Because only a single provider (other than the project leader) completed the lipid tracking 
forms during the evaluation period, additional analyses were done using the available data to 
ascertain if there any other differences between the providers.  Lipid data from the combined 
data set (baseline and post practice change samples) was analyzed with an independent t-test to 
compare the two providers.  There were differences noted between the providers in all lipid 
values measured (cholesterol, triglycerides, HDL, VLDL, LDL and non-HDL).  Provider One 
who completed the forms during the evaluation period had patients with lower mean levels of 
cholesterol, triglycerides, VLDL, LDL, and non-HDL than Provider Two.  Of those, there were 
statistically significant differences in cholesterol (p=0.000), LDL (p=0.009), and non-HDL 
(p=0.013).  These are three of the most significant lipid factors in cardiovascular risk.   
 In addition, the combined data set was used to evaluate any differences in providers for 
follow-up, „at or below goal‟, and use of statin medications.  Chi-square analyses were 
performed.  Comparison between Provider One and Provider Two for appropriate follow-up 
showed that there was a statistically significant difference between the two providers (p=0.002).  
Provider One had more patients who had appropriate follow-up.  Even though Provider Two had 
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a higher percentage of patients who were not at or below goal (25.3% v. 23.1%) chi-square 
analysis showed that there was no statistical difference between the two providers (p=0.727).  In 
addition, the two providers were compared on the use of statin medication for the treatment of 
HLD.  There was no difference noted between the two providers in the use of statin medications 
(p=0.235). 
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Chapter V: Summary, Discussion & Implications 
Congruence with the Theoretical Framework 
 This capstone project demonstrated congruence with the theoretical framework.  Rogers‟ 
Diffusion of Innovation Theory allows for the possibility that the innovation (practice change) 
might be rejected.  Ladd (2010) postulated that there is an additional step of reevaluation that is 
needed when the innovation is a practice change.  This reevaluation step can occur at two 
different points in the process.  After the initial rejection step and after the confirmation step, if 
the innovation is not formally adopted (Figure 5).  This step allows for the members to reassess 
the practice change and determine if there are any changes that can be made that would make the 
practice change more compatible with both the members and the practice in general.  The general 
concept for this reevaluation step is that it is difficult to assess whether or not a practice change 
concept will work until it is introduced into the systems.  In addition, if the members know that 
they will be able to have continuing input into the practice change, they may be more willing to 
adopt it.  The practice change using the lipid tracking form was not formally adopted by the 
practice.  However, the concept was generally well received and while the form in its current 
state was not adopted, a modified version the form is being developed that will track other 
chronic diseases as well.  Specific aspects regarding the lack of adoption of the practice change 
were reviewed in the context of Rogers Theory. 
 Adopter categories. 
 The theory identifies five adopter categories: (1) innovators; (2) early adopters; (3) the 
early majority; (4) the late majority; and (5) laggards.  The distribution of the adopter categories 
usually follows a normal distribution (Figure 6).  It can be difficult in a small practice have 
sufficient numbers for this distribution.  Even with intimate knowledge of the system, it is 
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difficult to determine into which categories people fall.  The innovator for this practice change 
was the project leader.  Provider One was an early adopter, and was involved in the process.  
Provider Two acted in the manner of a member of the early majority category however, after the 
evaluation phase, it was discovered that Provider Two was actually a laggard.  The system 
(practice) into which this innovation was introduced did not have the usual distribution in the 
adopter categories.  This is most likely due the small number of providers involved.  Other 
members of the ancillary staff who were in the late majority category did not significantly affect 
the distribution.   In order to assess the congruence of the theory with the practice change, the 
distribution of the people in each category needs to be assessed at the reevaluation stage to 
determine if there is sufficient distribution of the adopters in the system for the practice change 
to be successful in the future.   
 Factors that affect the rate of adoption. 
 In addition, Rogers describes specific factors that affect the rate of adoption.  These 
include: (1) the relative advantage; (2) compatibility within the existing system; (3) complexity; 
(4) trialability; and (5) observability.  In regards to this specific practice change there was a lack 
of perceived relative advantage.  It is difficult to overcome this without insinuating that there is a 
lack in current practice.  The proposed practice change did not possess sufficient compatibility 
with the current process in the practice.   Although it did have compatibility with other practices 
in the area, with which the staff was familiar.  The practice change was not complex and for the 
evaluation phase of the implementation the majority of the work that would become the 
responsibility of the ancillary staff was carried out by the project leader.  However, were the 
practice change to have been formally adopted, the ancillary staff would have been required to 
complete those tasks (inputting the most recent lab values in the form).   It may be that they 
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perceived that as complex.  The reevaluation step (Ladd, 2010) addresses the issue of trialability 
and was stressed during the process to encourage staff to be more willing to accept the practice 
change.  In addition, the reevaluation step can also demonstrate the relative advantage of the 
practice change.  Because the long term effects of adherence to lipid guidelines are not 
immediately measurable, there may be a lack of observability.  However, there are some aspects 
of this practice change, such as trends in lipid values, medication changes and adherence to 
follow-up, that would be documented on the form, that are more observable.  
 Diffusion of Innovations: Stages. 
 This practice change progressed through the stages described by Rogers (1962) and Ladd 
(2010).  It was assumed that the providers (both with many years of experience) had a basic 
knowledge of the treatment of lipid disorders.  That notwithstanding, they were each also 
provided with copies of the current guidelines.  This was the stage of knowledge attainment.  The 
second stage, the persuasion stage, was addressed by involving the providers in the process.  
Feedback on the lipid-tracking form was obtained and implemented in the final format of the 
form.  In addition, the development of a basic policy for routine follow-up was developed to be 
incorporated on the form.  During this stage, both providers demonstrated involvement in the 
proposed practice change.    
 The third stage, the decision making process, involved multiple conversations with the 
providers and staff regarding how the process would proceed.  Specific details such as where the 
form would be placing in the chart were addressed.  Once it was decided that the practice would 
proceed with the innovation, a timeline was developed.  In addition, responsibilities for specific 
aspects of the practice change were determined. During that stage, it was clear who the 
innovator, early adopter and early majority participants were.  During this stage, it was not 
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obvious to the project leader that there were a significant number of non-adopters.  Had that been 
the case the practice change would have needed to be reevaluated. 
 The fourth stage, the implementation stage, involved the use of the lipid-tracking forms.  
The implementation began as planned.  However, after the first week of the use of the lipid-
tracking forms, it became apparent that Provider Two was not participating in the practice 
change at all and that Provider One was not completing as many forms as anticipated.  It was 
unclear to the project leader why this was happening based upon previous indications of support.  
Therefore, additional conversations occurred with both providers to determine the issue.  During 
these conversations both providers verbalized support for the practice change, and support for the 
use of the forms.  In addition, the instructions for the use of the form (Appendix A) as well as the 
ATP-III guideline and Framingham risk scores were provided again to the providers.  Despite 
this, Provider Two still did not complete any of the forms.  Although Provider One did improve 
in the number of forms completed, it was still less than what had been anticipated.   
 The confirmation stage, stage five, is the confirmation stage when the practice is formally 
adopted.  Because of the distinct difference between the providers regarding the use of the form, 
especially with Provider Two failing to complete any forms, the practice change was not 
formally adopted.  The future of this practice change is technically in the reevaluation stage.  
However, based on the current practice dynamics, it will not be adopted practice wide.  It is 
suspected by this researcher that one of the biggest obstacles to the implementation of this 
practice change is the lack of perceived advantage to the current system.  It is also suspected that 
the lack of perceived advantage (over current practice) will be a significant roadblock in the 
implementation of any new practice change regardless of the system. 
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 Even with intimate knowledge of the practice setting it is difficult to anticipate how 
people will behave when faced with change.  Even though it was expected that there may have 
been some resistance to the practice change, and it was believed that those issues had been 
addressed, the actual outcomes were not anticipated.  While the project leader did not expect 
100% participation, it was certainly not anticipated that one of the providers would completely 
dismiss the practice change and be a laggard.  There are several lessons that can be learned from 
this.  The perception of relative advantage on the new practice is crucial to any practice change.  
The behaviors of participants prior to implementation, while indicative of future behaviors, 
cannot always be predicted or relied on.  The culture of the system (practice) is significant.  If the 
practice has a culture that has been resistant to change, or has not shown evidence of change, the 
probability that any new practice will be implemented is small, regardless of assurances to the 
contrary.  Words are only as good as the actions that follow.   
Discussion 
 There is a large body of evidence that has demonstrated that appropriate lipid 
management reduces cardiovascular morbidity and mortality.  In addition, it has been 
demonstrated that there is a distinct lack of adherence to lipid lowering guidelines for the 
management of lipid disorders.   There is evidence that the use of a paper based intervention 
could modify behavior.  The purpose of this capstone project was to evaluate the use of a paper 
lipid tracking tool in a primary care setting to determine if it would improve provider adherence 
to lipid guidelines.  One of the key project objectives was to demonstrate that the lipid tracking 
form increased the number of patient who had documented LDL goals.  Determination of a 
diagnosis of hyperlipidemia is relative to the goal that is determined by the provider.  If there is 
no documented goal or adequate documentation of cardiovascular risk, the patient may be 
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undertreated.  LDL goals are not static but are changing targets that need to be reevaluated 
frequently.  One of the criticisms of ATP-III is that it is too complicated (Sager, et al., 2010) and 
leads to too much variation in goals, especially in those at moderate risk. 
Limitations of the project. 
This project had several limitations.   One limitation was the use of a small practice.  The 
small practice had only two providers (other than the project leader) who were available to 
utilize the practice change.  Since there were only two providers, it became an issue when one 
provider (Provider Two) failed to participate in the project.  This left only one provider to 
contribute to the evaluation of the practice change.  Another limitation of the project was the 
length of the evaluation period.  In order to better evaluate the improvement in the patients‟ lipid 
values, a longer study of six months to one year would be needed.  In addition, there would need 
to be better use of the intervention.   
Project findings. 
 Even with the limitations, there were some positive findings.  Analyses of the baseline 
sample showed that there was already good adherence to some of the measures.  There was 
adherence demonstrated in screening for lipid disorders and documentation of a diagnosis of 
hyperlipidemia.  The evaluation of the use of medications was not able to be done because of 
individual provider preferences and lack of documentation of rationale.  Two measures were 
compared using the baseline sample and the post practice change samples.  These were the 
documentation of an LDL goal and appropriate follow-up for lipid disorders.  This capstone 
project did demonstrate that there was a statistically significant improvement in the number of 
patients with documented LDL goals (p=0.000).  While there was an increase in the number of 
patients who had proper follow-up for lipid disorders, it was not statistically significant 
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(p=0.457).  The project timeline did not allow for the project leader to assess whether or not 
there was an increase in the number of patients who were at or below goal. 
Implications 
 One of the benefits of the lipid tracking form is that it compiles all of the pertinent 
information in one place.  There is no need to search through a chart or remember a rationale.  
This project did demonstrate that the use of a simple paper lipid tracking from did improve 
provider adherence to lipid guidelines, but in only one of the four measures.  However that 
measure, documentation of LDL goals, is a critical step in treating hyperlipidemia.  It is 
anticipated that the new guidelines (ATP-IV), due to be released in the fall of 2012, will lower 
the current goals for primary prevention (Allison, 2010).  It will be to provider‟s and patient‟s 
benefit to develop tools to help improve provider adherence.  If this simple lipid tracking tool 
showed improvement even with only one provider participating, it is anticipated that 
improvement would also be achieved in other practices in which the providers where willing to 
utilize the forms.  In addition, the format could be adapted for use in electronic medical record 
system so that the information that is important to the management of hyperlipidemia such as, 
medication, labs, medication changes, and recommended follow-up could be displayed in one 
screen.  This project lays the groundwork for future study.  
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Figure 1: Average annual age-adjusted rate (deaths per 100,000) for people ages 35 years and 
older (CDC, 2009). 
 
 
Figure 2: Prevalence of elevated cholesterol and indices of increased cardiovascular risk broken 
down by gender and race (AHA, 2010). 













Figure 3: Rogers‟ Diffusion of Innovation (Rogers, 1962) 
 
 














Figure 4: Ladd‟s (2010) adaption of Rogers‟ Diffusion of Innovation for use in implementing 
practice change.
















Figure 5: Ladd‟s further adaption of Rogers‟ Diffusion of Innovation for use in implementing 
practice change. 





Figure 6: Diffusion of Innovation s-curve and normal distribution of adopter categories (Rogers, 
1962) 
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The form will be placed on the charts of patients (except derm visits and joint injection visits) 
coming into the office for the next few weeks.   
 
I will be placing the form on the charts after they are prepped and before you see them.  I will fill 
in the basic data (age and gender) and assign a study ID number.   
 
In addition, I will fill in the labs values from the most recent set of labs that are available to me 
when the chart has been prepped. 
 
 
When you see the patient, please fill in on the form at the time of the visit the following: 
 
1) Identify and check off the patients comorbidities 
2) Determine and document (on the form) the patients LDL goal 
3) List the patients current medications (OTC too), indicate none if on no lipid-lowering 
therapy 
4) Note any comments regarding current medication or change in medication (e.g. missed 
doses, non compliant, increase to Zocor 40, change to Crestor 5 etc.) 
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Appendix D: ATP-III Quick Reference Guide 
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Appendix E: Letter of Support 
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Appendix F: Framingham Risk Scores 
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